Initial Low-Dose Dacomitinib for First-Line Treatment of Patients With EGFR Exon 21-Mutated Non-Small-Cell Lung Cancer.

Background: Dacomitinib has demonstrated superior efficacy compared with first-generation tyrosine kinase inhibitors (TKIs) in patients with epidermal growth factor receptor (EGFR) exon 21-mutated non-small-cell lung cancer (NSCLC). However, the standard 45 mg dose often leads to a high incidence of...

Descripción completa

Detalles Bibliográficos

Publicado en:	Clinical Medicine Insights: Oncology Vol. 20; pp. 1 - 9
Autores principales:	Liu, Ke-Jun, Huang, Lin-Xuan, Jiang, Guan-Ming, Guo, Ning-Ning, Tan, Qing-Lin, Cai, Yan-Min, Chen, Shi-Yuan, Du, Wei, Fang, Nian-Xin, Jia, Jun
Formato:	research tables/charts Journal Article
Publicado:	Sage Publications Inc. 5/27/2026
Acceso en línea:	Ver este registro en EBSCOhost